• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

个性化心血管疾病预测与治疗——现有策略及新型系统医学工具综述

Personalized Cardiovascular Disease Prediction and Treatment-A Review of Existing Strategies and Novel Systems Medicine Tools.

作者信息

Björnson Elias, Borén Jan, Mardinoglu Adil

机构信息

Department of Biology and Biological Engineering, Chalmers University of TechnologyGothenburg, Sweden; Department of Molecular and Clinical Medicine/Wallenberg Laboratory, University of GothenburgGothenburg, Sweden.

Department of Molecular and Clinical Medicine/Wallenberg Laboratory, University of Gothenburg Gothenburg, Sweden.

出版信息

Front Physiol. 2016 Jan 26;7:2. doi: 10.3389/fphys.2016.00002. eCollection 2016.

DOI:10.3389/fphys.2016.00002
PMID:26858650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4726746/
Abstract

Cardiovascular disease (CVD) continues to constitute the leading cause of death globally. CVD risk stratification is an essential tool to sort through heterogeneous populations and identify individuals at risk of developing CVD. However, applications of current risk scores have recently been shown to result in considerable misclassification of high-risk subjects. In addition, despite long standing beneficial effects in secondary prevention, current CVD medications have in a primary prevention setting shown modest benefit in terms of increasing life expectancy. A systems biology approach to CVD risk stratification may be employed for improving risk-estimating algorithms through addition of high-throughput derived omics biomarkers. In addition, modeling of personalized benefit-of-treatment may help in guiding choice of intervention. In the area of medicine, realizing that CVD involves perturbations of large complex biological networks, future directions in drug development may involve moving away from a reductionist approach toward a system level approach. Here, we review current CVD risk scores and explore how novel algorithms could help to improve the identification of risk and maximize personalized treatment benefit. We also discuss possible future directions in the development of effective treatment strategies for CVD through the use of genome-scale metabolic models (GEMs) as well as other biological network-based approaches.

摘要

心血管疾病(CVD)仍然是全球主要的死因。CVD风险分层是一种重要工具,用于区分异质人群并识别有患CVD风险的个体。然而,最近的研究表明,当前风险评分的应用会导致对高风险受试者的大量误分类。此外,尽管目前的CVD药物在二级预防中具有长期的有益效果,但在一级预防中,就延长预期寿命而言,其益处并不显著。可以采用系统生物学方法进行CVD风险分层,通过添加高通量衍生的组学生物标志物来改进风险评估算法。此外,个性化治疗益处的建模可能有助于指导干预措施的选择。在医学领域,认识到CVD涉及大型复杂生物网络的扰动,药物开发的未来方向可能是从还原论方法转向系统水平方法。在此,我们回顾当前的CVD风险评分,并探讨新算法如何有助于改进风险识别并最大化个性化治疗益处。我们还讨论了通过使用基因组规模代谢模型(GEM)以及其他基于生物网络的方法,在开发有效的CVD治疗策略方面可能的未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ad/4726746/a7fb9ad5457b/fphys-07-00002-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ad/4726746/a7fb9ad5457b/fphys-07-00002-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ad/4726746/a7fb9ad5457b/fphys-07-00002-g0001.jpg

相似文献

1
Personalized Cardiovascular Disease Prediction and Treatment-A Review of Existing Strategies and Novel Systems Medicine Tools.个性化心血管疾病预测与治疗——现有策略及新型系统医学工具综述
Front Physiol. 2016 Jan 26;7:2. doi: 10.3389/fphys.2016.00002. eCollection 2016.
2
Personalized Management of Cardiovascular Disorders.心血管疾病的个体化管理。
Med Princ Pract. 2017;26(5):399-414. doi: 10.1159/000481403. Epub 2017 Sep 11.
3
Tuberculosis结核病
4
Genome-scale modeling of human metabolism - a systems biology approach.人类代谢的基因组规模建模 - 系统生物学方法。
Biotechnol J. 2013 Sep;8(9):985-96. doi: 10.1002/biot.201200275. Epub 2013 Apr 24.
5
6
Systems Biology Applications to Decipher Mechanisms and Novel Biomarkers in CNS Trauma系统生物学在解析中枢神经系统创伤机制及新型生物标志物中的应用
7
Understanding the Causes and Implications of Endothelial Metabolic Variation in Cardiovascular Disease through Genome-Scale Metabolic Modeling.通过基因组尺度代谢模型理解心血管疾病中内皮代谢变异的原因及影响。
Front Cardiovasc Med. 2016 Apr 18;3:10. doi: 10.3389/fcvm.2016.00010. eCollection 2016.
8
Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.心血管疾病中的药物基因组学挑战:药物实例及未来整合至临床实践的考量
Curr Pharm Biotechnol. 2017;18(3):231-241. doi: 10.2174/1389201018666170123153626.
9
Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification头部损伤的转化代谢组学:基于体外核磁共振波谱的代谢物定量分析探索脑代谢功能障碍
10

引用本文的文献

1
Evaluating Cardiovascular Risk Factors Among Healthcare Professionals in Iran.评估伊朗医疗保健专业人员的心血管危险因素。
Med Sci Monit. 2025 Mar 15;31:e947409. doi: 10.12659/MSM.947409.
2
Prediction of the Duration to Next Admission for an Acute Affective Episode in Patients with Bipolar I Disorder.双相I型障碍患者急性情感发作至下次入院时间的预测
Clin Psychopharmacol Neurosci. 2023 May 30;21(2):262-270. doi: 10.9758/cpn.2023.21.2.262.
3
Cardiovascular health research priorities in the United Arab Emirates.阿联酋的心血管健康研究重点。

本文引用的文献

1
Do genome-scale models need exact solvers or clearer standards?基因组规模模型需要精确求解器还是更清晰的标准?
Mol Syst Biol. 2015 Oct 14;11(10):831. doi: 10.15252/msb.20156157.
2
Reply to "Do genome-scale models need exact solvers or clearer standards?".对《基因组规模模型需要精确求解器还是更清晰的标准?》的回复
Mol Syst Biol. 2015 Oct 14;11(10):830. doi: 10.15252/msb.20156548.
3
Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome.量化饮食对人类肠道微生物组的代谢变化。
Front Public Health. 2023 Mar 9;11:1130716. doi: 10.3389/fpubh.2023.1130716. eCollection 2023.
4
Improvement in the diagnosis and practices of emergency healthcare providers for heat emergencies after HEAT (heat emergency awareness & treatment) an educational intervention: a multicenter quasi-experimental study.在 HEAT(热应急意识和治疗)教育干预之后,急诊医疗提供者对热应急的诊断和实践的改善:一项多中心准实验研究。
BMC Emerg Med. 2023 Jan 31;23(1):12. doi: 10.1186/s12873-022-00768-5.
5
Recent advances in nonalcoholic fatty liver disease metabolomics.非酒精性脂肪性肝病代谢组学的最新进展。
Clin Mol Hepatol. 2021 Oct;27(4):553-559. doi: 10.3350/cmh.2021.0127. Epub 2021 Jun 8.
6
Current Status and Future Prospects of Genome-Scale Metabolic Modeling to Optimize the Use of Mesenchymal Stem Cells in Regenerative Medicine.基因组规模代谢建模在优化间充质干细胞在再生医学中的应用的现状与未来展望
Front Bioeng Biotechnol. 2020 Mar 31;8:239. doi: 10.3389/fbioe.2020.00239. eCollection 2020.
7
Network Medicine: A Clinical Approach for Precision Medicine and Personalized Therapy in Coronary Heart Disease.网络医学:冠心病精准医学和个体化治疗的临床方法。
J Atheroscler Thromb. 2020 Apr 1;27(4):279-302. doi: 10.5551/jat.52407. Epub 2019 Nov 12.
8
Glial cells influence cardiac permittivity as evidenced through in vitro and in silico models.神经胶质细胞通过体外和计算机模型影响心脏电容率。
Biofabrication. 2019 Dec 2;12(1):015014. doi: 10.1088/1758-5090/ab4c0a.
9
Novel Biomarkers of Early Atherosclerotic Changes for Personalised Prevention of Cardiovascular Disease in Cervical Cancer and Human Papillomavirus Infection.用于宫颈癌和人乳头瘤病毒感染的个体化心血管疾病预防的早期动脉粥样硬化变化的新型生物标志物。
Int J Mol Sci. 2019 Jul 30;20(15):3720. doi: 10.3390/ijms20153720.
10
Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities.纳米抗体偶联和格式细菌的合成联合体,用于预防和治疗靶向微生物组失调相关疾病和合并症的干预措施。
Microb Biotechnol. 2019 Jan;12(1):58-65. doi: 10.1111/1751-7915.13355.
Cell Metab. 2015 Aug 4;22(2):320-31. doi: 10.1016/j.cmet.2015.07.001.
4
Modeling cancer metabolism on a genome scale.在基因组规模上模拟癌症代谢。
Mol Syst Biol. 2015 Jun 30;11(6):817. doi: 10.15252/msb.20145307.
5
Flux balance analysis predicts essential genes in clear cell renal cell carcinoma metabolism.通量平衡分析预测透明细胞肾细胞癌代谢中的必需基因。
Sci Rep. 2015 Jun 4;5:10738. doi: 10.1038/srep10738.
6
Using Genome-scale Models to Predict Biological Capabilities.使用基因组规模模型预测生物学能力。
Cell. 2015 May 21;161(5):971-987. doi: 10.1016/j.cell.2015.05.019.
7
Proteome- and transcriptome-driven reconstruction of the human myocyte metabolic network and its use for identification of markers for diabetes.基于蛋白质组和转录组驱动的人类心肌细胞代谢网络重建及其在糖尿病标志物识别中的应用。
Cell Rep. 2015 May 12;11(6):921-933. doi: 10.1016/j.celrep.2015.04.010. Epub 2015 Apr 30.
8
Logical transformation of genome-scale metabolic models for gene level applications and analysis.用于基因水平应用和分析的基因组规模代谢模型的逻辑转换。
Bioinformatics. 2015 Jul 15;31(14):2324-31. doi: 10.1093/bioinformatics/btv134. Epub 2015 Mar 2.
9
Reconstruction of genome-scale human metabolic models using omics data.利用组学数据重建全基因组规模的人类代谢模型。
Integr Biol (Camb). 2015 Aug;7(8):859-68. doi: 10.1039/c5ib00002e.
10
Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling.通过基因组规模代谢建模鉴定人类癌细胞系的抗生长因子
Sci Rep. 2015 Feb 2;5:8183. doi: 10.1038/srep08183.